BK多瘤病毒相关肾病的诊断与治疗标准
本文综述肾移植后BK多瘤病毒相关肾病(BKPyVAN)的诊断与治疗现状。减少免疫抑制可降低早期移植物失败率但可能诱发急性排斥,中长期移植物结局受病毒损伤和宿主免疫反应影响。肾活检是金标准但假阴性常见,BKPyV DNA血症用于筛查但缺乏国际标准化,亟需随机对照试验和新型治疗评估。
要点
- 肾活检是BKPyVAN诊断金标准,但因病变局灶性假阴性常见。
- 减少免疫抑制是主要治疗手段,但需平衡急性排斥风险。
- BKPyV DNA血症用于筛查,但检测方法缺乏国际标准化。
核心结论
- BKPyVAN是肾移植重要并发症,减少免疫抑制可降低早期移植物失败但可能诱发急性排斥。
- 中长期移植物结局受病毒损伤和宿主免疫反应共同影响。
- 诊断与治疗缺乏高质量随机对照试验证据,BKPyV DNA检测未标准化。
研究设计与样本
- 本文为综述,总结BKPyVAN诊断与治疗现行标准并讨论病理生理、诊断、结局预测和管理新进展。
主要发现
- 减少免疫抑制可降低BKPyVAN所致早期移植物失败率,但可能诱发急性排斥。
- BKPyVAN对中长期移植物结局有负面影响,可能由病毒损伤和免疫抑制减少后宿主抗移植物免疫反应增强共同所致。
- 肾活检是金标准,但因BKPyVAN局灶性假阴性常见。
- BKPyV DNA血症(定量PCR)已确立为筛查试验,但目前无(国际)国家标准化。
- 缺乏关于最佳免疫抑制减少策略及临床治疗药物的随机对照试验。
关键数值与推荐
- 肾活检为BKPyVAN诊断金标准。
- BKPyV DNA血症(定量PCR)为筛查试验。
- 目前无BKPyV DNA检测的国际标准化。
临床怎么用
- 肾移植后应筛查BKPyV DNA血症,阳性者需进一步评估。
- 确诊BKPyVAN后以减少免疫抑制为主要治疗,但需监测急性排斥。
- 肾活检阴性不能完全排除BKPyVAN,因病变局灶性。
局限性
- 缺乏关于免疫抑制减少策略和治疗药物的随机对照试验。
- BKPyV DNA检测缺乏国际标准化,难以比较中心间数据。
- BKPyV基本生物学尚未充分理解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BK polyomavirus (BKPyV) is recognized as a significant viral complication of kidney transplantation. Prompt immunosuppression reduction reduces early graft failure rates due to BK polyomavirus-associated nephropathy (BKPyVAN), however, modulation of immunosuppression can lead to acute rejection. Medium-to-long-term graft outcomes are negatively affected by BKPyVAN, probably due to a combination of virus-induced graft damage and host immune responses against graft alloantigens potentiated by immunosuppression reduction. Kidney biopsy remains the gold-standard diagnostic test, however, false-negative findings are common due to the focal nature of BKPyVAN. BKPyV DNAemia, as measured by quantitative polymerase chain reaction, is established as a screening test but there is at present no (inter)national standardization of these assays to allow collation and comparison of data between centres. Randomized controlled trials are lacking both in terms of optimal immunosuppression reduction strategies, and for the medications variably used to attempt treatment in clinical practice. Much of the fundamental biology of BKPyV is not yet understood, and further elucidation is required to promote rational direct-acting antiviral drug design. Insights into the role of adaptive immunity in control of BKPyV have informed the design of novel treatments such as adoptive immunotherapies and neutralizing antibodies that require evaluation in clinical studies. Here, we review the current standards of diagnosis and treatment of BKPyVAN and discuss novel developments in the pathophysiology, diagnosis, outcome prediction, and management.
引用
- Al-Talib M, Welberry-Smith M, Macdonald A, et al. BK Polyomavirus-associated nephropathy - diagnostic and treatment standard. Nephrol Dial Transplant. 2025. PMID: 39794277. doi:10.1093/ndt/gfaf002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。